Jannik Grodt Schmidt’s Post

Are we finally out of the Biotech Winter? Last week saw 5 Biotech's with successful rounds of more than $100 million. 1. Freenome $254M 2. BioAge Labs $170M 3. Latigo Biotherapeutics, Inc. $135M 4. ProfoundBio $112M 5. Alys Pharmaceuticals $100M The AI sector also had a number of successful deals last week, its starting to feel a bit like 2021 again! We are all hoping for a Dream of Spring (some of us still want the Winds of Winter though). #biotech #investment #gameofthrones

Known for its abundant forests, smorgasbords, and, of course, the famed Europop group ABBA, Sweden has a thriving economy that largely depends on manufacturing and exports. Plus, the country’s life science sector recorded a net turnover of almost SEK 365 billion ($34 billion) in 2020 – an increase of just over SEK 158 billion ($14.8 billion) since 2014 – and it is still ever-growing. Labiotech.eu discusses eight #biotech companies in Sweden spearheading the country’s biotech scene. * Amferia * Anocca * Aprea Therapeutics * Asgard Therapeutics * BioInvent International AB * Diamyd Medical * Hamlet BioPharma * Modus Therapeutics Holding AB Find out more via https://lnkd.in/ew7FAXYQ

Exciting update! Venkat Nelabhotla, the CEO at Vyome Therapeutics, Inc., is going to be a keynote speaker at our 7th Annual Drug Discovery Summit, Princeton,NJ. Grab your spot now by reaching out to- Sid@alcor-wealth.com. Be a part of this awesome summit where we dive deep into the world of drug discovery. #ADDP #DrugDiscovery #Innovation #Summit2024 #biotechnology Secure your spot and let's make this summit a blast! 🚀

📌 Syngene Announces First Quarter Results for FY 2025!   Commenting on the first quarter, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “First quarter performance was broadly flat, in line with our expectations, reflecting the dip in funding for US biotechs that has impacted our sector over the last two years. However, the value of US biotech funding has seen a marked improvement in the first half of 2024. It will take a while for this funding to flow into outsourcing activities and Syngene is in a strong position to capture a significant share of the upturn in biotech spending in the months ahead.”  Read the full press release, link in the comments section 🔗 #Syngene #SyngeneQ1Results #FY25 #Biotech #Pharma

Catch up on the recent Prescient Therapeutics (ASX: PTX) investor briefing with CEO Steven Yatomi-Clarke. Watch now 👉 https://hubs.ly/Q02slP1V0 Steven discussed the journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point. #Biotech #CellTherapies #CancerTreatment

📰📰 As you have seen this week, 2024 looks to be an amazing year for our industry. Here at Nucleus Biologics, we also have some big plans! Navigate over to our NEWS section to stay up to date on the latest, including our recent collaboration agreement with Core Biogenesis. Our blog section also contains interesting industry insights and in-depth analysis of cell culture products and processes, new product releases, and more. #biotech #lifescience #cellculture https://hubs.ly/Q02gHqfj0

Dimerix Limited (ASX:DXB, OTC:SBMJF) CEO and managing director Dr Nina Webster is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth. Dimerix is is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need. Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with #InflammatoryDiseases, such as kidney or lung diseases. Dimerix encourages collaboration and is well positioned to discuss partnering and product development. Watch at #Proactive #ProactiveInvestors #KidneyDisease #LungDisease #Biotech #Biopharmaceutcials Elisha Newell https://lnkd.in/eMT7kHqg

Despite a general negative trend for Nordick biotech and healthcare stocks, the best stocks increased their share price by 48-98%. The Danish stocks fared in general better than the Nordic counterparts. In the past week, Curasight received its first milestone payment from its collaboration deal with Curium, Saniona published the prospectus for their upcoming rights issue, and price targets were issued for Genmab and Zealand Pharma. 8 of the 20 companies had a positive share price development the past week and 12 companies have had a positive share price performance year-to-date. Read more: https://lnkd.in/dtzYJ-Ar Ascendis Pharma Biosergen CS MEDICA Curasight Evaxion Biotech A/S ExpreS2ion Biotechnologies FluoGuide A/S Genmab Gubra IO Biotech PILA PHARMA Saniona SynAct Pharma ViroGates Zealand Pharma Y-mAbs Therapeutics, Inc. 2cureX - Individualizing Cancer Treatment #Biotech #pharma #stocks

Patient-derived cells (PDCs): the future of drug discovery Drug discovery is known for its high attrition rates that lead to significant investments in both cost and time. However, the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development. In this blog, the Inaphaea team explores the potential of PDCs and their role in shaping the future of drug discovery. Read the blog here: https://bit.ly/43gvTcL #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #PDCs

Kentucky has the potential to become an engine for biotech innovation. From Apellis Pharmaceuticals to DesiCorp Inc to Creosalus, Kentucky companies are creating world class life science technologies. KYINNO focused attention on this opportunity as captured in their recent article "How Kentucky is becoming a favorite in biotech". XLerateHealth is proud to be an important contributor to this evolving biotech ecosystem in Kentucky and the southeast region. Read the full article here: https://bit.ly/3T3sKcL